

# NOVARTIS

## Reimagining Medicine

**Novartis International AG is a global healthcare company based in Switzerland with a purpose to reimagine medicine and extend people's lives. The company seeks to deliver transformative treatments by pushing the boundaries of medical paradigms and exploring possibilities to cure disease, intervening earlier in chronic illnesses, and finding ways to exponentially enhance quality of life. The company has embraced the use of digital technologies, advanced analytics and artificial intelligence to continually drive innovation and improve efficiency.**

Novartis began its Singapore operations in 1986. The company currently employs around 1,000 associates working across divisions covering innovative generic and biosimilar medicines, the operation of two manufacturing plants, and its Asia-Pacific regional headquarters. Novartis Singapore is one of the leaders in clinical trials with patients at the center of the science, making it a priority to explore areas of unmet medical need to bring new hope to patients.

### COMMITMENT TO PATIENTS AND CAREGIVERS

The company has significantly invested in research and development which underpins its commitment to using science-based innovation to address some of society's most challenging healthcare issues.

But what is even more important for Novartis is the collaboration with pa-

tient communities around the world to discover new ways to improve and extend people's lives. It has been a strategy of the pharma company to work together to refine outcomes for patients and thereby changing the practice of medicine.

Novartis actively seeks out and listens to insights from the patient community throughout the development and commercialization process for their medicines. In that way Novartis has a better understanding of the patient community perspective, deliver a better healthcare experience and faster access to transformational treatments, for the mutual benefit of patients, healthcare systems and Novartis.

Research and development (R&D) at Novartis is the heartbeat of the company. Its R&D efforts span two units: the Novartis Institutes for BioMedical Research (NIBR) and Global Drug Development (GDD). NIBR leads drug

discovery and development from concept to early clinical evaluation. GDD leads clinical development to ensure pivotal registrational programs for regulatory approval and access to patients. Novartis engages patient communities to understand their needs and remain committed to patients who take part in its clinical trials. Ranked third in the 2021 Access to Medicine Index R&D category, Novartis was recognized as the only company that commits to both post-trial access for all eligible clinical trial participants and considers post-trial affordability for countries in scope.

### EXPANDING ACCESS TO NOVARTIS' MEDICINES

Beside working with the patient community, Novartis is also engaged with other stakeholders, such as governments, payers, healthcare professionals and peer companies, to help get patients the medicine they need. Therefore the organisation is implementing access strategies for all their new medicines based on three principles: addressing the needs of underserved populations through research and development; further improving affordability of their medicines; and supporting approaches to strengthen healthcare systems.

### DIGITAL AMBITION

Novartis has embarked on an ambitious transformation to become the leading medicines company powered by data science and digital technologies.

With the use of AI the pharma industry can improve patients' lives and optimize the healthcare ecosystem. These technological developments come with both opportunities and challenges. Therefore Novartis is dedicated to deploying AI systems in a transparent manner and through responsible channels.

### NOVARTIS BIOME: A CATALYST FOR IMPACTFUL DIGITAL COLLABORATION

The pharma industry is facing major healthcare challenges on the road to digitalisation which require the collaboration of multiple ecosystem agents.



Novartis is committed to using science-based innovation to address some of society's most challenging healthcare issues.

Novartis Biome Singapore is Novartis' first innovation hub for the Asia Pacific Middle East and Africa region.

For Novartis, partnering with the best players in the tech world combined with their deep scientific experience will help to scale digital solutions that can improve and extend patients' lives.

With the creation of Novartis Biome the company created a bridge which helped their partners to become an extension of their own teams so they can collaborate as easily and productively as possible. It benefits joint innovation and the co-development of digital solutions at scale.

Novartis Biome Singapore is Novartis' first innovation hub for the Asia Pacific Middle East and Africa region dedicated to driving and managing partnerships with digital health start-ups, innovators and thought leaders in healthcare transformation. Novartis Biome Singapore is the latest inclusion of the global Biome network, following launches in San Francisco (USA), London (UK), Paris (France), Hyderabad (India), Montreal (Canada), Shanghai (China) and Berlin (Germany).

Biome Singapore will connect Novartis teams to the external digital ecosystem, allowing them to identify, establish and build on strong collaborations that produce significantly innovative and scalable solutions for patients. Similarly, partners who join this global network have access to an array of assets and expertise from the wider Novartis portfolio, to bring transformative impact.



### ACCELERATING DIGITAL TRANSFORMATION


On December 4, 2019, Amazon Web Services (AWS) announced a strategic collaboration with Novartis that will leverage AWS's broadest portfolio of cloud services to build an enterprise-wide data and analytics platform that will transform business operations. Starting within Novartis Technical Operations, this multiyear alliance aims to put real-time analytics in the hands of associates, empowering them to make better business decisions and increase efficiencies across manufacturing processes and supply chain.

Novartis is thus collaborating with AWS to build an enterprise-wide data and analytics platform to transform the way medicines are manufactured and delivered.

### GLOBAL RECOGNITION IN HEALTHCARE

Novartis has been showcasing consistently excellent performance on all areas related to innovative healthcare as evidenced by the global recognition accorded to the company over the years. Notably, Novartis rose to #3 in the Fortune World's Most Admired Companies Pharmaceuticals Industry list in 2021, from #4 in 2020 and 2019. Novartis ranks #3 in Innovation and #2 In Global Competitiveness (the same as 2020) in the same survey conducted by Fortune.

Novartis has also maintained its position in the 2021 Access to Medicine Index, leading in its approach to product delivery, while performing strongly across all other areas of the Index.



Novartis Singapore manufacturing plant.



**Novartis (Singapore) Pte Ltd**  
20 Pasir Panjang Rd, #10-25/28 Mapletree Business City, Singapore 117439  
W: [www.novartis.com.sg](http://www.novartis.com.sg)  
T: +65 6722 6010